 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...126127128129130131132133134135136...143144» |
- pegvorhyaluronidase alfa (PEGPH20) / Halozyme, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection (clinicaltrials.gov) - Sep 16, 2014
P=N/A, N=10, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
New P2 trial: Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients (clinicaltrials.gov) - Sep 15, 2014
P2, N=24, Not yet recruiting, Sponsor: Foamix Ltd.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P3 trial, Metastases: AGMT_HNO_PN: Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck (clinicaltrials.gov) - Sep 11, 2014
P3, N=146, Not yet recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, P4 data, Enrollment change, Metastases: EMR62241-508: Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=221, Completed, Sponsor: Merck KGaA
Recruiting --> Completed | N=300 --> 221
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment (clinicaltrials.gov) - Aug 29, 2014
P2, N=13, Terminated, Sponsor: City of Hope Medical Center
Recruiting --> Completed | N=300 --> 221 Completed --> Terminated; Study was terminated early due to lack of efficacy.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change, Metastases: EMR 62202-509: A Korean Post-marketing Surveillance Study on Erbitux (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=730, Completed, Sponsor: Merck KGaA
Completed --> Terminated; Study was terminated early due to lack of efficacy. Recruiting --> Completed | N=600 --> 730
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Trial primary completion date, FDG PET, Metastases: 3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx (clinicaltrials.gov) - Aug 27, 2014
P0, N=30, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Completed | N=600 --> 730 Phase classification: P2 --> P0 | Trial primary completion date: Sep 2014 --> Aug 2011
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer (clinicaltrials.gov) - Aug 25, 2014
P=N/A, N=57, Active, not recruiting, Sponsor: Centre Oscar Lambret
Phase classification: P2 --> P0 | Trial primary completion date: Sep 2014 --> Aug 2011 Recruiting --> Active, not recruiting | N=100 --> 57 | Trial primary completion date: Nov 2013 --> May 2012
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 25, 2014
P2, N=128, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=100 --> 57 | Trial primary completion date: Nov 2013 --> May 2012 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (clinicaltrials.gov) - Aug 22, 2014
P2, N=28, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck (clinicaltrials.gov) - Aug 21, 2014
P4, N=70, Recruiting, Sponsor: Medical University Innsbruck
Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting
- || telisotuzumab (h224G11) / AbbVie
Trial primary completion date, Metastases: Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 19, 2014
P1, N=124, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
New P1 trial, Metastases: TORERO: Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Aug 15, 2014
P1, N=42, Recruiting, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4 (clinicaltrials.gov) - Aug 12, 2014
P=N/A, N=150, Recruiting, Sponsor: ICORG- All Ireland Cooperative Oncology Research Group
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: May 2014 --> Dec 2019
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Trial primary completion date: Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Aug 12, 2014
P2, N=100, Active, not recruiting, Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Trial primary completion date: May 2014 --> Dec 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2013 --> Jan 2014
- ||| gedatolisib (PF-05212384) / Celcuity
Trial initiation date, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Aug 11, 2014
P2, N=159, Recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2013 --> Jan 2014 Initiation date: Apr 2014 --> Nov 2013
- |||| Tabrecta (capmatinib) / Incyte, Novartis
Enrollment open, Combination therapy: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (clinicaltrials.gov) - Aug 8, 2014
P1/2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Apr 2014 --> Nov 2013 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux (clinicaltrials.gov) - Aug 7, 2014
P3, N=406, Active, not recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Surgery, Metastases: Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 6, 2014
P1/2, N=47, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2014 --> Dec 2015
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: RTOG-1016: Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer (clinicaltrials.gov) - Aug 5, 2014
P3, N=706, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: TROG 12.01: Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 4, 2014
P3, N=200, Recruiting, Sponsor: Trans-Tasman Radiation Oncology Group (TROG)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Tabrecta (capmatinib) / Incyte, Novartis
New P1/2 trial, Combination therapy: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy (clinicaltrials.gov) - Aug 1, 2014
P1/2, N=60, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Trial initiation date, Trial primary completion date, Surgery, Metastases: ECKINOXE: Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer (clinicaltrials.gov) - Jul 30, 2014
P2, N=186, Recruiting, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> May 2012 | Trial primary completion date: Feb 2014 --> May 2012
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Na (clinicaltrials.gov) - Jul 30, 2014
P2, N=107, Completed, Sponsor: EMD Serono
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> May 2012 | Trial primary completion date: Feb 2014 --> May 2012 Active, not recruiting --> Completed
- || Gilotrif (afatinib) / Boehringer Ingelheim
Trial primary completion date, Metastases: BIBW 2992 (Afatinib) in Head & Neck Cancer (clinicaltrials.gov) - Jul 27, 2014
P2, N=124, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial primary completion date: Jun 2011 --> Mar 2010
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Combination therapy, Metastases: Erlotinib in Combination With Cetuximab (clinicaltrials.gov) - Jul 25, 2014
P1, N=48, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jun 2011 --> Mar 2010 Trial primary completion date: Apr 2015 --> Apr 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=140, Recruiting, Sponsor: Southwest Oncology Group
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Sep 2014 --> Jul 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jul 23, 2014
P2, N=46, Recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Trial primary completion date: Sep 2014 --> Jul 2015 Trial primary completion date: Sep 2014 --> Sep 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Surgery, Metastases: Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer (clinicaltrials.gov) - Jul 17, 2014
P3, N=720, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Sep 2014 --> Sep 2016 Trial primary completion date: Jun 2014 --> Jun 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer (clinicaltrials.gov) - Jul 16, 2014
P2, N=37, Completed, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Jun 2014 --> Jun 2016 Active, not recruiting --> Completed
- Votrient (pazopanib) / Novartis, BeiGene, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date: Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Jul 15, 2014
P1, N=33, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Jun 2015
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=40, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Dec 2014 --> Jun 2015 Trial primary completion date: May 2013 --> Dec 2014
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: FOCULM: FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 15, 2014
P2, N=138, Recruiting, Sponsor: Sun Yat-sen University
Trial primary completion date: May 2013 --> Dec 2014 N=106 --> 138
- ||| gedatolisib (PF-05212384) / Celcuity
Trial initiation date, Metastases: A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 14, 2014
P2, N=159, Recruiting, Sponsor: Pfizer
N=106 --> 138 Initiation date: Nov 2013 --> Apr 2014
- elgemtumab (LJM-716) / Novartis, MorphoSys
Enrollment change, Trial withdrawal, Combination therapy, Metastases: Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients (clinicaltrials.gov) - Jul 14, 2014
P1/2, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Initiation date: Nov 2013 --> Apr 2014 N=128 --> 0 | Not yet recruiting --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer (clinicaltrials.gov) - Jul 14, 2014
P1, N=22, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=128 --> 0 | Not yet recruiting --> Withdrawn N=17 --> 22
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Monotherapy, Metastases: PIK-ORL: Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive (clinicaltrials.gov) - Jul 12, 2014
P2, N=70, Recruiting, Sponsor: Centre Leon Berard
N=17 --> 22 Trial primary completion date: Sep 2014 --> Mar 2016
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, abituzumab (EMD 525797) / EMD Serono, SFJ Pharma
Trial primary completion date, Combination therapy, Metastases: POSEIDON: EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 12, 2014
P1/2, N=229, Active, not recruiting, Sponsor: Merck KGaA
Trial primary completion date: Sep 2014 --> Mar 2016 Trial primary completion date: Dec 2013 --> Dec 2014
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Surgery: RTOG-0617: High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 12, 2014
P3, N=500, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Trial primary completion date: Dec 2013 --> Dec 2014 Trial primary completion date: May 2014 --> May 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: A Study of Mitomycin C, Irinotecan, and Cetuximab (clinicaltrials.gov) - Jul 12, 2014
P2, N=13, Terminated, Sponsor: University of Michigan Cancer Center
Trial primary completion date: May 2014 --> May 2016 Completed --> Terminated; The study was discontinued due to the death of a co-investigator and a second co-investigator leaving the institution.
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: EMR62202-512: A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN) (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=215, Completed, Sponsor: Merck KGaA
Completed --> Terminated; The study was discontinued due to the death of a co-investigator and a second co-investigator leaving the institution. Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: IMPACT-CRC: Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 4, 2014
P1/2, N=85, Recruiting, Sponsor: VU University Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Trial primary completion date, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Jul 2, 2014
P1, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2015 --> Feb 2016
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
P4 data, Trial primary completion date, Combination therapy, Metastases: EMR 62241-510: A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=0, Withdrawn, Sponsor: Merck KGaA
Trial primary completion date: Feb 2015 --> Feb 2016 Trial primary completion date: Jul 2014 --> Mar 2009
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
P4 data, Enrollment change, Trial primary completion date, Combination therapy, Metastases: EMR 62241-510: A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck (clinicaltrials.gov) - Jul 2, 2014
P=N/A, N=0, Withdrawn, Sponsor: Merck KGaA
Trial primary completion date: Jul 2014 --> Mar 2009 N=600 --> 0 | Trial primary completion date: Jul 2014 --> Mar 2009
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Metastases: Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=27, Not yet recruiting, Sponsor: Rutgers, The State University of New Jersey
- ||| prexasertib (ACR-368) / Acrivon Therap
Enrollment open, Combination therapy, Metastases: A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer (clinicaltrials.gov) - Jul 1, 2014
P1, N=70, Recruiting, Sponsor: Eli Lilly and Company
N=600 --> 0 | Trial primary completion date: Jul 2014 --> Mar 2009 Not yet recruiting --> Recruiting
- Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open: PD 0332991 and Cetuximab in Patients With Incurable SCCHN (clinicaltrials.gov) - Jul 1, 2014
P1/2, N=42, Recruiting, Sponsor: Washington University School of Medicine
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || elgemtumab (LJM-716) / Novartis, MorphoSys
Trial primary completion date, Combination therapy, Metastases: Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients (clinicaltrials.gov) - Jun 27, 2014
P1/2, N=128, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Aug 2017
- || lumretuzumab (RG7116) / Roche
Trial primary completion date, Combination therapy, Metastases: A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin (clinicaltrials.gov) - Jun 27, 2014
P1, N=160, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2016 --> Aug 2017 Trial primary completion date: Jan 2016 --> Aug 2015